Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 86

1.

Outcome of very elderly chronic myeloid leukaemia patients treated with imatinib frontline.

Crugnola M, Castagnetti F, Breccia M, Ferrero D, Trawinska MM, Abruzzese E, Annunziata M, Stagno F, Tiribelli M, Binotto G, Bonifacio M, Fava C, Iurlo A, Bucelli C, Mansueto G, Gozzini A, Falzetti F, Montefusco E, Crisà E, Gugliotta G, Russo S, Cedrone M, RussoRossi A, Pregno P, Isidori A, Mauro E, Atelda R, Giglio G, Celesti F, Sorà F, Storti S, D'Addosio A, Galimberti S, Orlandi E, Calistri E, Bocchia M, Cavazzini F, Rege Cambrin G, Orofino N, Luciano L, Sgherza N, Rosti G, Latagliata R, Capodanno I.

Ann Hematol. 2019 Oct;98(10):2329-2338. doi: 10.1007/s00277-019-03767-y. Epub 2019 Aug 7.

PMID:
31392461
2.

Deferasirox in the treatment of iron overload during myeloproliferative neoplasms in fibrotic phase: does ferritin decrement matter?

Di Veroli A, Campagna A, De Muro M, Maurillo L, Trawinska MM, LeonettiCrescenzi S, Petriccione L, Romano A, D'Addosio A, Cenfra A, Montanaro M, Felici S, Andriani A, Carmosino I, Niscola P, Montefusco E, Breccia M, Latagliata R.

Leuk Res. 2019 Jan;76:65-69. doi: 10.1016/j.leukres.2018.11.012. Epub 2018 Dec 4.

PMID:
30578958
3.

High platelet count at diagnosis is a protective factor for thrombosis in patients with essential thrombocythemia.

Latagliata R, Montanaro M, Cedrone M, Di Veroli A, Spirito F, Santoro C, Leonetti Crescenzi S, Porrini R, Di Giandomenico J, Villivà N, Spadea A, Rago A, De Gregoris C, Romano A, Anaclerico B, De Muro M, Felici S, Breccia M, Montefusco E, Bagnato A, Cimino G, Majolino I, Mazzucconi MG, Alimena G, Andriani A; Gruppo Laziale, SMPC Ph1.

Thromb Res. 2017 Aug;156:168-171. doi: 10.1016/j.thromres.2017.06.023. Epub 2017 Jun 21.

PMID:
28662484
4.

Role of treatment on the development of secondary malignancies in patients with essential thrombocythemia.

Santoro C, Sperduti I, Latagliata R, Baldacci E, Anaclerico B, Avvisati G, Breccia M, Buccisano F, Cedrone M, Cimino G, De Gregoris C, De Muro M, Di Veroli A, Leonetti Crescenzi S, Montanaro M, Montefusco E, Porrini R, Rago A, Spadea A, Spirito F, Villivà N, Andriani A, Alimena G, Mazzucconi MG.

Cancer Med. 2017 Jun;6(6):1233-1239. doi: 10.1002/cam4.1081. Epub 2017 May 23.

5.

Chronic myeloid leukaemia with extreme thrombocytosis at presentation: incidence, clinical findings and outcome.

Sora F, Iurlo A, Sica S, Latagliata R, Annunziata M, Galimberti S, Castagnetti F, Pregno P, Sgherza N, Celesti F, Bocchia M, Gozzini A, Fava C, Cattaneo D, Crugnola M, Montefusco E, Mauro E, Capodanno I, Breccia M.

Br J Haematol. 2018 Apr;181(2):267-270. doi: 10.1111/bjh.14553. Epub 2017 Feb 7. No abstract available.

PMID:
28169426
6.

Imatinib and polypharmacy in very old patients with chronic myeloid leukemia: effects on response rate, toxicity and outcome.

Iurlo A, Nobili A, Latagliata R, Bucelli C, Castagnetti F, Breccia M, Abruzzese E, Cattaneo D, Fava C, Ferrero D, Gozzini A, Bonifacio M, Tiribelli M, Pregno P, Stagno F, Vigneri P, Annunziata M, Cavazzini F, Binotto G, Mansueto G, Russo S, Falzetti F, Montefusco E, Gugliotta G, Storti S, D'Addosio AM, Scaffidi L, Cortesi L, Cedrone M, Rossi AR, Avanzini P, Mauro E, Spadea A, Celesti F, Giglio G, Isidori A, Crugnola M, Calistri E, Sorà F, Rege-Cambrin G, Sica S, Luciano L, Galimberti S, Orlandi EM, Bocchia M, Tettamanti M, Alimena G, Saglio G, Rosti G, Mannucci PM, Cortelezzi A.

Oncotarget. 2016 Nov 29;7(48):80083-80090. doi: 10.18632/oncotarget.11657.

7.

Spleen enlargement is a risk factor for thrombosis in essential thrombocythemia: Evaluation on 1,297 patients.

Andriani A, Latagliata R, Anaclerico B, Spadea A, Rago A, Di Veroli A, Spirito F, Porrini R, De Muro M, Crescenzi Leonetti S, Villivà N, De Gregoris C, Montefusco E, Polverelli N, Santoro C, Breccia M, Cimino G, Majolino I, Mazzucconi MG, Vianelli N, Alimena G, Montanaro M, Palandri F.

Am J Hematol. 2016 Mar;91(3):318-21. doi: 10.1002/ajh.24269.

8.

Chelation efficacy and erythroid response during deferasirox treatment in patients with myeloproliferative neoplasms in fibrotic phase.

Latagliata R, Montagna C, Porrini R, Di Veroli A, Leonetti SC, Niscola P, Ciccone F, Spadea A, Breccia M, Maurillo L, Rago A, Spirito F, Cedrone M, De Muro M, Montanaro M, Andriani A, Bagnato A, Montefusco E, Alimena G.

Eur J Haematol. 2016 Jun;96(6):643-9. doi: 10.1111/ejh.12674. Epub 2015 Sep 18.

PMID:
26277477
9.

Are there alternative ways to quantify the real benefit of novel agents in oncology? - the 'death pace'.

Formica V, Montefusco E, Roselli M.

Cancer Biol Ther. 2015;16(2):187-8. doi: 10.1080/15384047.2014.1002368. No abstract available.

10.

Hemoglobin levels and circulating blasts are two easily evaluable diagnostic parameters highly predictive of leukemic transformation in primary myelofibrosis.

Rago A, Latagliata R, Montanaro M, Montefusco E, Andriani A, Crescenzi SL, Mecarocci S, Spirito F, Spadea A, Recine U, Cicconi L, Avvisati G, Cedrone M, Breccia M, Porrini R, Villivà N, De Gregoris C, Alimena G, D'Arcangelo E, Guglielmelli P, Lo-Coco F, Vannucchi A, Cimino G.

Leuk Res. 2015 Mar;39(3):314-7. doi: 10.1016/j.leukres.2015.01.001. Epub 2015 Jan 12.

PMID:
25636356
11.

Age influences initial dose and compliance to imatinib in chronic myeloid leukemia elderly patients but concomitant comorbidities appear to influence overall and event-free survival.

Breccia M, Luciano L, Latagliata R, Castagnetti F, Ferrero D, Cavazzini F, Trawinska MM, Annunziata M, Stagno F, Tiribelli M, Binotto G, Crisà E, Musto P, Gozzini A, Cavalli L, Montefusco E, Iurlo A, Russo S, Cedrone M, Rossi AR, Pregno P, Endri M, Spadea A, Molica M, Giglio G, Celesti F, Sorà F, Storti S, D'Addosio A, Cambrin GR, Isidori A, Sica S, Abruzzese E, Speccha G, Rosti G, Alimena G.

Leuk Res. 2014 Oct;38(10):1173-6. doi: 10.1016/j.leukres.2014.06.020. Epub 2014 Jul 7.

PMID:
25047978
12.

Thrombosis and survival in essential thrombocythemia: a regional study of 1,144 patients.

Montanaro M, Latagliata R, Cedrone M, Spadea A, Rago A, Di Giandomenico J, Spirito F, Porrini R, De Muro M, Leonetti SC, Villivà N, De Gregoris C, Breccia M, Montefusco E, Santoro C, Cimino G, Majolino I, Mazzucconi MG, Alimena G, Andriani A.

Am J Hematol. 2014 May;89(5):542-6. doi: 10.1002/ajh.23685. Epub 2014 Feb 21.

13.

Genomic analysis of therapy-related acute promyelocytic leukemias arising after malignant and non-malignant disorders.

Ottone T, Hasan SK, Voso MT, Ledda A, Montefusco E, Fenu S, Pagoni M, Hubmann M, Lunghi M, Platzbecker U, Lo-Coco F.

Am J Hematol. 2014 Mar;89(3):346-7. doi: 10.1002/ajh.23646. No abstract available.

14.

High incidence of post-transplant cytomegalovirus reactivations in myeloma patients undergoing autologous stem cell transplantation after treatment with bortezomib-based regimens: a survey from the Rome transplant network.

Marchesi F, Mengarelli A, Giannotti F, Tendas A, Anaclerico B, Porrini R, Picardi A, Cerchiara E, Dentamaro T, Chierichini A, Romeo A, Cudillo L, Montefusco E, Tirindelli MC, De Fabritiis P, Annino L, Petti MC, Monarca B, Arcese W, Avvisati G; Rome Transplant Network.

Transpl Infect Dis. 2014 Feb;16(1):158-64. doi: 10.1111/tid.12162. Epub 2013 Nov 12.

PMID:
24215479
15.

Bone marrow aspiration and biopsy-related pain management.

Sollazzo F, Tendas A, Conte E, Bianchi MP, Niscola P, Cupelli L, Mauroni MR, Molinari V, D'Apolito A, Pilozzi V, Cacciaraichi S, Viggiani C, Pignatelli AC, Annibali O, Mengarelli A, Dentamaro T, de Fabritiis P, Ferrari A, Montefusco E, Arcese W; Rome Transplant; Network Quality of Life Working Party.

Ann Hematol. 2014 Jun;93(6):1061-2. doi: 10.1007/s00277-013-1926-7. Epub 2013 Oct 22. No abstract available.

PMID:
24146234
16.

Imatinib in very elderly patients with chronic myeloid leukemia in chronic phase: a retrospective study.

Latagliata R, Ferrero D, Iurlo A, Cavazzini F, Castagnetti F, Abruzzese E, Fava C, Breccia M, Annunziata M, Stagno F, Tiribelli M, Binotto G, Mansueto G, Gozzini A, Russo S, Cavalli L, Montefusco E, Gugliotta G, Cedrone M, Russo Rossi A, Avanzini P, Pregno P, Mauro E, Spadea A, Celesti F, Giglio G, Isidori A, Crugnola M, Calistri E, Sorà F, Storti S, D'Addosio A, Rege-Cambrin G, Luciano L, Alimena G.

Drugs Aging. 2013 Aug;30(8):629-37. doi: 10.1007/s40266-013-0088-6.

PMID:
23681399
17.

Identification of emerging FLT3 ITD-positive clones during clinical remission and kinetics of disease relapse in acute myeloid leukaemia with mutated nucleophosmin.

Ottone T, Zaza S, Divona M, Hasan SK, Lavorgna S, Laterza S, Cicconi L, Panetta P, Di Giandomenico J, Cittadini M, Ciardi C, Montefusco E, Franchi A, Annino L, Venditti A, Amadori S, Lo-Coco F.

Br J Haematol. 2013 May;161(4):533-40. doi: 10.1111/bjh.12288. Epub 2013 Mar 11.

PMID:
23480665
18.

Impact of BCR-ABL mutations on response to dasatinib after imatinib failure in elderly patients with chronic-phase chronic myeloid leukemia.

Tiribelli M, Latagliata R, Luciano L, Castagnetti F, Gozzini A, Cambrin GR, Annunziata M, Stagno F, Pregno P, Albano F, Abruzzese E, Musto P, Montefusco E, Fava C, Fanin R, Pane F, Rosti G, Breccia M, Alimena G, Vigneri P.

Ann Hematol. 2013 Jan;92(2):179-83. doi: 10.1007/s00277-012-1591-2. Epub 2012 Oct 10.

PMID:
23053188
19.

Comparative molecular analysis of therapy-related and de novo acute promyelocytic leukemia.

Ottone T, Cicconi L, Hasan SK, Lavorgna S, Divona M, Voso MT, Montefusco E, Melillo L, Barragán E, Platzbecker U, Giannì L, Hubmann M, Pagoni M, Amadori S, Lo-Coco F.

Leuk Res. 2012 Apr;36(4):474-8. doi: 10.1016/j.leukres.2011.10.015. Epub 2011 Nov 8.

PMID:
22071137
20.

Dasatinib is safe and effective in unselected chronic myeloid leukaemia elderly patients resistant/intolerant to imatinib.

Latagliata R, Breccia M, Castagnetti F, Stagno F, Luciano L, Gozzini A, Ulisciani S, Cavazzini F, Annunziata M, Sorà F, Rossi AR, Pregno P, Montefusco E, Abruzzese E, Crisà E, Musto P, Tiribelli M, Binotto G, Occhini U, Feo C, Vigneri P, Santini V, Fava C, Rosti G, Alimena G.

Leuk Res. 2011 Sep;35(9):1164-9. doi: 10.1016/j.leukres.2011.05.015. Epub 2011 Jun 25.

PMID:
21705080
21.

Hammersmith score application identifies chronic myeloid leukemia patients with poor prognosis before treatment with second-generation tyrosine kinase inhibitors.

Breccia M, Stagno F, Gozzini A, Abruzzese E, Latagliata R, Rossi AR, Sorà F, Porrini R, Vigneri P, Trawinska M, Montefusco E, Sica S, Specchia G, Santini V, Alimena G.

Am J Hematol. 2011 Jun;86(6):523-5. doi: 10.1002/ajh.22020. No abstract available.

22.

The incidence of pleural and pericardial effusion is not higher in patients receiving dasatinib at low doses. (Reply).

Visani G, Breccia M, Montefusco E, Morra E, Santini V, Isidori A.

Haematologica. 2011 Apr;96(4):e23-4; author reply e25. doi: 10.3324/haematol.2011.041319. No abstract available.

23.

Frontline imatinib treatment of chronic myeloid leukemia: no impact of age on outcome, a survey by the GIMEMA CML Working Party.

Gugliotta G, Castagnetti F, Palandri F, Breccia M, Intermesoli T, Capucci A, Martino B, Pregno P, Rupoli S, Ferrero D, Gherlinzoni F, Montefusco E, Bocchia M, Tiribelli M, Pierri I, Grifoni F, Marzocchi G, Amabile M, Testoni N, Martinelli G, Alimena G, Pane F, Saglio G, Baccarani M, Rosti G; Gruppo Italiano Malattie Ematologiche dell'Adulto CML Working Party.

Blood. 2011 May 26;117(21):5591-9. doi: 10.1182/blood-2010-12-324228. Epub 2011 Mar 30.

PMID:
21450900
24.

Dasatinib, even at low doses, is an effective second-line therapy for chronic myeloid leukemia patients resistant or intolerant to imatinib. Results from a real life-based Italian multicenter retrospective study on 114 patients.

Visani G, Breccia M, Gozzini A, Specchia G, Montefusco E, Morra E, Annunziata M, Camera A, Cavazzini F, Stagno F, Pregno P, Usala E, Santini V, Piccaluga PP, Isidori A.

Am J Hematol. 2010 Dec;85(12):960-3. doi: 10.1002/ajh.21871. No abstract available.

25.

Use of arsenic trioxide in secondary acute promyelocytic leukemia developing after treatment of multiple sclerosis with mitoxantrone.

Ammatuna E, Montefusco E, Pacilli M, Divona M, Ardiri D, Centonze D, Lo-Coco F.

Leuk Lymphoma. 2009 Jul;50(7):1217-8. doi: 10.1080/10428190902912486. No abstract available.

PMID:
19479616
26.

Identification of a potential "hotspot" DNA region in the RUNX1 gene targeted by mitoxantrone in therapy-related acute myeloid leukemia with t(16;21) translocation.

Ottone T, Hasan SK, Montefusco E, Curzi P, Mays AN, Chessa L, Ferrari A, Conte E, Noguera NI, Lavorgna S, Ammatuna E, Divona M, Bovetti K, Amadori S, Grimwade D, Lo-Coco F.

Genes Chromosomes Cancer. 2009 Mar;48(3):213-21. doi: 10.1002/gcc.20633.

PMID:
19023877
27.

Low absolute lymphocyte count is a poor prognostic factor in diffuse-large-B-cell-lymphoma.

Cox MC, Nofroni I, Ruco L, Amodeo R, Ferrari A, La Verde G, Cardelli P, Montefusco E, Conte E, Monarca B, Aloe-Spiriti MA.

Leuk Lymphoma. 2008 Sep;49(9):1745-51. doi: 10.1080/10428190802226425.

PMID:
18798109
28.

Molecular analysis of t(15;17) genomic breakpoints in secondary acute promyelocytic leukemia arising after treatment of multiple sclerosis.

Hasan SK, Mays AN, Ottone T, Ledda A, La Nasa G, Cattaneo C, Borlenghi E, Melillo L, Montefusco E, Cervera J, Stephen C, Satchi G, Lennard A, Libura M, Byl JA, Osheroff N, Amadori S, Felix CA, Voso MT, Sperr WR, Esteve J, Sanz MA, Grimwade D, Lo-Coco F.

Blood. 2008 Oct 15;112(8):3383-90. doi: 10.1182/blood-2007-10-115600. Epub 2008 Jul 23.

29.

Male patients with chronic myeloid leukemia treated with imatinib involved in healthy pregnancies: report of five cases.

Breccia M, Cannella L, Montefusco E, Frustaci A, Pacilli M, Alimena G.

Leuk Res. 2008 Mar;32(3):519-20. Epub 2007 Sep 4. No abstract available.

PMID:
17804066
30.

Intrathecal anti-CD20 antibody: an effective and safe treatment for leptomeningeal lymphoma.

Antonini G, Cox MC, Montefusco E, Ferrari A, Conte E, Morino S, Latino P, Trasimeni G, Monarca B.

J Neurooncol. 2007 Jan;81(2):197-9. Epub 2006 Aug 26.

PMID:
16937012
31.

Achieving a major molecular response at the time of a complete cytogenetic response (CCgR) predicts a better duration of CCgR in imatinib-treated chronic myeloid leukemia patients.

Iacobucci I, Saglio G, Rosti G, Testoni N, Pane F, Amabile M, Poerio A, Soverini S, Bassi S, Cilloni D, Bassan R, Breccia M, Lauria F, Izzo B, Merante S, Frassoni F, Paolini S, Montefusco E, Baccarani M, Martinelli G; GIMEMA Working Party on Chronic Myeloid Leukemia.

Clin Cancer Res. 2006 May 15;12(10):3037-42.

32.

Comparison between patients with Philadelphia-positive chronic phase chronic myeloid leukemia who obtained a complete cytogenetic response within 1 year of imatinib therapy and those who achieved such a response after 12 months of treatment.

Iacobucci I, Rosti G, Amabile M, Poerio A, Soverini S, Cilloni D, Testoni N, Abruzzese E, Montefusco E, Ottaviani E, Iuliano F, Russo D, Gobbi M, Alimena G, Martino B, Terragna C, Pane F, Saglio G, Baccarani M, Martinelli G.

J Clin Oncol. 2006 Jan 20;24(3):454-9.

PMID:
16421422
33.

Elderly patients with Ph+ chronic myelogenous leukemia (CML): results of imatinib mesylate treatment.

Latagliata R, Breccia M, Carmosino I, Sarlo C, Montefusco E, Mancini M, Natalino F, Chistolini A, De Cuia R, Russo E, Morano GS, Biondo F, Spadea A, Mandelli F, Alimena G.

Leuk Res. 2005 Mar;29(3):287-91. Erratum in: Leuk Res. 2005 Sep;29(9):1099. Roberto, Latagliata [corrected to Latagliata, Roberto]; Massimo, Breccia [corrected to Breccia, Massimo]; Ida, Carmosino [corrected to Carmosino, Ida]; Chiara, Sarlo [corrected to Sarlo, Chiara]; Enrico, Montefusco [corrected to Montefusco, Enrico]; Marco,.

PMID:
15661264
34.

IFN-alpha promotes the rapid differentiation of monocytes from patients with chronic myeloid leukemia into activated dendritic cells tuned to undergo full maturation after LPS treatment.

Gabriele L, Borghi P, Rozera C, Sestili P, Andreotti M, Guarini A, Montefusco E, Foà R, Belardelli F.

Blood. 2004 Feb 1;103(3):980-7. Epub 2003 Oct 2.

PMID:
14525781
35.

High-dose hydroxyurea in the treatment of poor-risk myeloid leukemias.

Petti MC, Tafuri A, Latagliata R, Aloe Spiriti MA, Montefusco E, Mancini M, Meloni G, Petrucci MT, Spadea A, Redi R, Alimena G, Mandelli F.

Ann Hematol. 2003 Aug;82(8):476-480. doi: 10.1007/s00277-003-0693-2. Epub 2003 Jun 26.

PMID:
12835916
36.

Chronic myeloid leukemia cells resistant to interferon-alpha lack STAT1 expression.

Landolfo S, Guarini A, Riera L, Gariglio M, Gribaudo G, Cignetti A, Cordone I, Montefusco E, Mandelli F, Foa R.

Hematol J. 2000;1(1):7-14.

PMID:
11920164
37.

A randomized study of interferon-alpha versus interferon-alpha and low-dose arabinosyl cytosine in chronic myeloid leukemia.

Baccarani M, Rosti G, de Vivo A, Bonifazi F, Russo D, Martinelli G, Testoni N, Amabile M, Fiacchini M, Montefusco E, Saglio G, Tura S; Italian Cooperative Study Group on Myeloid Leukemia.

Blood. 2002 Mar 1;99(5):1527-35.

PMID:
11861264
38.

Melphalan treatment in patients with myelofibrosis with myeloid metaplasia.

Petti MC, Latagliata R, Spadea T, Spadea A, Montefusco E, Aloe Spiriti MA, Avvisati G, Breccia M, Pescarmona E, Mandelli F.

Br J Haematol. 2002 Mar;116(3):576-81. Erratum in: Br J Haematol 2002 Jun;117(4):1002.

PMID:
11849213
39.

Chronic myeloid leukemia and interferon-alpha: a study of complete cytogenetic responders.

Bonifazi F, de Vivo A, Rosti G, Guilhot F, Guilhot J, Trabacchi E, Hehlmann R, Hochhaus A, Shepherd PC, Steegmann JL, Kluin-Nelemans HC, Thaler J, Simonsson B, Louwagie A, Reiffers J, Mahon FX, Montefusco E, Alimena G, Hasford J, Richards S, Saglio G, Testoni N, Martinelli G, Tura S, Baccarani M; Europena Study Group on Interferon in Chronic Myeloid Leukemia; Italian Cooperative Study Group on CML; France Intergroup of CML; German CML Study Group; UK Medical Research Council Working Party on CML; Spanish CML Study Group; Australian CML Study Group; Swedish CML Study Group.

Blood. 2001 Nov 15;98(10):3074-81. Review.

PMID:
11698293
40.

Molecular remission following high-dose hydroxyurea and fludarabine plus cytarabine in a patient with simultaneous acute myeloid leukemia and low-grade lymphoma.

Montefusco E, Fazi F, Cordone I, Ariola C, Nanni M, Spadea A, Spiriti MA, Fenu S, Mandelli F, Petti MC.

Leuk Lymphoma. 2001 Feb;40(5-6):671-4.

PMID:
11426540
41.

Ten-year follow-up of a single center prospective trial of unmanipulated peripheral blood stem cell autograft and interferon-alpha in early phase chronic myeloyd leukemia.

Meloni G, Capria S, Vignetti M, Alimena G, de Fabritiis P, Montefusco E, Mandelli F.

Haematologica. 2001 Jun;86(6):596-601.

42.

Phenotypic and functional characterization of the host immune compartment of chronic myeloid leukaemia patients in complete haematological remission.

Guarini A, Breccia M, Montefusco E, Petti MC, Zepparoni A, Vitale A, Foa R.

Br J Haematol. 2001 Apr;113(1):136-42.

PMID:
11328293
43.

Testing Sokal's and the new prognostic score for chronic myeloid leukaemia treated with alpha-interferon. Italian Cooperative Study Group on Chronic Myeloid Leukaemia.

Bonifazi F, De Vivo A, Rosti G, Tiribelli M, Russo D, Trabacchi E, Fiacchini M, Montefusco E, Baccarani M.

Br J Haematol. 2000 Nov;111(2):587-95.

PMID:
11122107
44.

A case-control study of the effects of hydroxyurea on circulating cortisol levels in patients with acute myelogenous leukemia and chronic myeloproliferative disorders.

Navarra P, Aloe-Spiriti MA, Boccarini F, Montefusco E, Latagliata R, Preziosi P, Petti MC.

Pharmacol Res. 2000 Oct;42(4):389-92.

PMID:
10988000
45.

Acute myeloblastic leukemia secondary to myelodysplasia (MDS-AML): a comparison of remission induction with three drugs versus standard two-drugs induction.

Latagliata R, Breccia M, Pulsoni A, Aloe Spiriti MA, D'Elia GM, Spadea A, Montefusco E, Luzi G, Betrò P, Petti MC.

Leuk Lymphoma. 2000 Feb;36(5-6):539-41.

PMID:
10784399
46.

[Treatment of acute and chronic leukemias].

Mandelli F, Montefusco E.

Recenti Prog Med. 1999 Nov;90(11):605-12. Review. Italian.

PMID:
10608151
47.

Polycythemia vera treated with pipobroman as single agent: low incidence of secondary leukemia in a cohort of patients observed during 20 years (1971-1991).

Petti MC, Spadea A, Avvisati G, Spadea T, Latagliata R, Montefusco E, Cosenza M, Malagnino F.

Leukemia. 1998 Jun;12(6):869-74.

48.

BCR-ABL antisense oligodeoxynucleotide in vitro purging and autologous bone marrow transplantation for patients with chronic myelogenous leukemia in advanced phase.

de Fabritiis P, Petti MC, Montefusco E, De Propris MS, Sala R, Bellucci R, Mancini M, Lisci A, Bonetto F, Geiser T, Calabretta B, Mandelli F.

Blood. 1998 May 1;91(9):3156-62.

PMID:
9558370
49.

Use of granulocyte-macrophage colony-stimulating factor (GM-CSF) in combination with hydroxyurea as post-transplant therapy in chronic myelogenous leukemia patients autografted with unmanipulated hematopoietic cells.

Carlo-Stella C, Regazzi E, Andrizzi C, Savoldo B, Garau D, Montefusco E, Vignetti M, Mandelli F, Rizzoli V, Meloni G.

Haematologica. 1997 May-Jun;82(3):291-6.

50.

Etoposide, intermediate-dose cytarabine and carboplatin (VAC): a combination therapy for the blastic phase of chronic myelogenous leukemia.

Montefusco E, Petti MC, Alimena G, Latagliata R, Celesti F, Capria S, Amadori S, Avvisati G, Mandelli F.

Ann Oncol. 1997 Feb;8(2):175-9.

PMID:
9093727

Supplemental Content

Loading ...
Support Center